{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["136(5)"],"submitter":["Handa N"],"funding":["Astellas Pharma","Pfizer","Pfizer Inc"],"pubmed_abstract":["Objectives
To evaluate the longitudinal transcriptomic changes that occurred over time in patients from the ENACT trial (ClinicalTrials.gov identifier: NCT02799745). ENACT evaluated patients with low- or intermediate-risk prostate cancer, comparing the efficacy and safety of enzalutamide plus active surveillance (AS) to AS alone.Patients and methods
Gene-expression profiling was conducted using the Decipher Genomic Resource for Intelligent Discovery (GRID) platform (Veracyte, Inc.) on 131 patient samples (enzalutamide plus AS: n = 57; AS alone: n = 74) collected at screening, Year 1, and Year 2. Pre-defined GRID signatures were analysed for associations with biological and clinical features, including immune activity, treatment sensitivity, metastatic risk, and molecular su"],"journal":["BJU international"],"pagination":["920-929"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12522525"],"repository":["biostudies-literature"],"pubmed_title":["Transcriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamide."],"pmcid":["PMC12522525"],"pubmed_authors":["Shore ND","Ross A","Handa N","Davicioni E","Russell D","Cooperberg MR","Proudfoot JA","Schaeffer EM","Zhao X","Iwata KK","Liu Y","Elsouda D","Kuperman G"],"additional_accession":[]},"is_claimable":false,"name":"Transcriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamide.","description":"Objectives
To evaluate the longitudinal transcriptomic changes that occurred over time in patients from the ENACT trial (ClinicalTrials.gov identifier: NCT02799745). ENACT evaluated patients with low- or intermediate-risk prostate cancer, comparing the efficacy and safety of enzalutamide plus active surveillance (AS) to AS alone.Patients and methods
Gene-expression profiling was conducted using the Decipher Genomic Resource for Intelligent Discovery (GRID) platform (Veracyte, Inc.) on 131 patient samples (enzalutamide plus AS: n = 57; AS alone: n = 74) collected at screening, Year 1, and Year 2. Pre-defined GRID signatures were analysed for associations with biological and clinical features, including immune activity, treatment sensitivity, metastatic risk, and molecular su","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-05-09T03:23:07.842Z","creation":"2026-05-09T03:12:18.503Z"},"accession":"S-EPMC12522525","cross_references":{"pubmed":["40742002"],"doi":["10.1111/bju.16861"]}}